<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23585663</PMID>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1945-7197</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>98</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of clinical endocrinology and metabolism</Title>
<ISOAbbreviation>J. Clin. Endocrinol. Metab.</ISOAbbreviation>
</Journal>
<ArticleTitle>A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults.</ArticleTitle>
<Pagination>
<MedlinePgn>2595-603</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1210/jc.2013-1437</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Administration of daily recombinant human GH (rhGH) poses a considerable challenge to patient compliance. Reduced dosing frequency may improve treatment adherence and potentially overall treatment outcomes.</AbstractText>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study assessed the safety and tolerability and the potential for achieving IGF-I levels within the target range in adults with GH deficiency after a single dose of the long-acting rhGH analog, VRS-317.</AbstractText>
<AbstractText Label="DESIGN" NlmCategory="METHODS">This was a randomized, double-blind, placebo-controlled, single ascending dose study.</AbstractText>
<AbstractText Label="PATIENTS" NlmCategory="METHODS">Fifty adults with growth hormone deficiency (mean age, 45 years) were studied in 5 treatment groups of 10 subjects each (8 active drug and 2 placebo).</AbstractText>
<AbstractText Label="SETTING" NlmCategory="METHODS">The study was conducted in 17 adult endocrinology centers in North America and Europe.</AbstractText>
<AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Adverse events, laboratory safety assessments, and VRS-317 pharmacokinetics and pharmacodynamics (IGF-I and IGF binding protein-3) were analyzed.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">At 0.80 mg/kg, VRS-317 had a mean terminal elimination half-life of 131 hours. Single VRS-317 doses of 0.05, 0.10, 0.20, 0.40, and 0.80 mg/kg (approximately equivalent to daily rhGH doses of 0.3-5.0 Î¼g/kg over 30 d) safely increased the amplitude and duration of IGF-I responses in a dose-dependent manner. After a single 0.80 mg/kg dose, serum IGF-I was maintained in the normal range between -1.5 and 1.5 SD values for a mean of 3 weeks. No unexpected or serious adverse events were observed.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The elimination half-life for VRS-317 is 30- to 60-fold longer and stimulates more durable IGF-I responses than previously studied rhGH products. Prolonged IGF-I responses do not come at the expense of overexposure to high IGF-I levels. The pharmacokinetics and pharmacodynamics combined with the observed safety profile indicate the potential for safe and effective monthly dosing.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yuen</LastName>
<ForeName>Kevin C J</ForeName>
<Initials>KC</Initials>
<AffiliationInfo>
<Affiliation>Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Conway</LastName>
<ForeName>Gerard S</ForeName>
<Initials>GS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Popovic</LastName>
<ForeName>Vera</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Merriam</LastName>
<ForeName>George R</ForeName>
<Initials>GR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bailey</LastName>
<ForeName>Timothy</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hamrahian</LastName>
<ForeName>Amir H</ForeName>
<Initials>AH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Biller</LastName>
<ForeName>Beverly M K</ForeName>
<Initials>BM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kipnes</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moore</LastName>
<ForeName>Jerome A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Humphriss</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bright</LastName>
<ForeName>George M</ForeName>
<Initials>GM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cleland</LastName>
<ForeName>Jeffrey L</ForeName>
<Initials>JL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList>
<AccessionNumber>NCT01359488</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>UL1RR024140</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1 UL1 RR025758-04</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UL1 TR000439</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UL1 RR025758</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UL1 RR024140</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>04</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Clin Endocrinol Metab</MedlineTA>
<NlmUniqueID>0375362</NlmUniqueID>
<ISSNLinking>0021-972X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>12629-01-5</RegistryNumber>
<NameOfSubstance UI="D019382">Human Growth Hormone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>67763-96-6</RegistryNumber>
<NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019382">Human Growth Hormone</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000172">deficiency</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007334">Insulin-Like Growth Factor I</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2013</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2013</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2013</Year>
<Month>8</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">23585663</ArticleId>
<ArticleId IdType="pii">jc.2013-1437</ArticleId>
<ArticleId IdType="doi">10.1210/jc.2013-1437</ArticleId>
<ArticleId IdType="pmc">PMC3667252</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Clin Endocrinol Metab. 2005 Dec;90(12):6431-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16159930</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Endocrinol. 2005 Jan;152(1):67-75</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15762189</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2006 Aug;91(8):2926-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16720652</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes Obes Metab. 2007 Jan;9(1):11-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17199714</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Endocrinol. 2007 Dec;157(6):695-700</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18057375</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arch Dis Child. 2008 Feb;93(2):147-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17768149</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocr Pract. 2008 Mar;14(2):143-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18308651</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocr Rev. 2009 Apr;30(2):152-77</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19240267</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2009 Aug;94(8):2702-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19509104</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Biotechnol. 2009 Dec;27(12):1186-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19915550</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocr Pract. 2009 Sep-Oct;15 Suppl 2:1-29</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20228036</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2010 Jul;95(7):3411-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20427496</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Sci (Lond). 2010 Dec;119(11):483-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20597861</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocrinology. 2010 Sep;151(9):4410-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20660071</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2011;6(1):e16223</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21305004</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2011 Mar;96(3):681-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21177789</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2011 Jun;96(6):1718-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21411551</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2011 Jun;96(6):1587-609</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21602453</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2011 Jun;96(6):1668-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21602459</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Endocrinol. 2011 Sep;165(3):401-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21724838</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2012 Feb;97(2):400-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22162481</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2012 Apr;97(4):E521-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22319035</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pharm Sci. 2012 Aug;101(8):2744-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22678811</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pediatr Endocrinol Metab. 2002 May;15 Suppl 2:715-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12092685</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2002 Oct;87(10):4508-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12364427</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Growth Horm IGF Res. 2004 Feb;14(1):45-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14700554</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Endocrinol (Oxf). 2004 Apr;60(4):442-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15049958</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2004 Jul;89(7):3224-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15240596</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2004 Jul;89(7):3234-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15240597</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arch Dis Child. 1979 Aug;54(8):609-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">507915</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 1991 Feb;72(2):374-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1991807</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 1998 May;83(5):1668-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9589675</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 1998 Nov;83(11):3913-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9814468</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Endocrinol (Oxf). 2004 Dec;61(6):683-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15579181</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pediatr Endocrinol Rev. 2005 Feb;2 Suppl 3:327-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16456500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>